What's New
Press Releases
1,200+ People Impacted by Young-Onset Dementia Gather for AFTD’s Annual Education Conference
More than one thousand people impacted by frontotemporal degeneration (FTD), the most common dementia under 60, came together to connect, learn, and engage with a community that understands the disease at the Association for Frontotemporal Degeneration’s (AFTD) first-ever hybrid Education…
Donald Newhouse Honored for Work Targeting Primary Progressive Aphasia, All Forms of Most Common Dementia under 60
On Wednesday night, at the Ziegfeld Ballroom in New York City, The Association for Frontotemporal Degeneration (AFTD) honored Donald Newhouse at its 2022 Hope Rising Benefit. Donald lost his wife, Susan Marley Newhouse, to primary progressive aphasia, a form of…
New Report Will Help the FDA to Evaluate Future Treatments for Frontotemporal Degeneration
Today, AFTD released Frontotemporal Degeneration (FTD): A Voice of the Patient Report. This report will provide the FDA with data and insights to evaluate future studies and treatments for FTD, the most common form of dementia under 60. As one…
Serving Young-Onset Dementia Awareness Hot
If you’ve never experienced the mix of pure adrenaline and instant regret that comes from taking a quick shot of hot sauce, a new campaign can help you check that off your list, for a good cause. Short for frontotemporal…
Holloway Family Fund Established to Expand AFTD’s Research Initiatives
AFTD today announced the creation of The Holloway Family Fund, supported by an initial $2 million donation from AFTD Board Member Kristin Holloway. The fund, which was created in honor of the Holloway family’s journey with FTD, aims to further…
Landmark $20MM Donation Fuels AFTD’s Work Targeting FTD, Most Common Dementia under 60
AFTD is grateful to announce the creation of The Donald and Susan Newhouse Fund at AFTD. The Fund has been launched through a generous $20 million donation from AFTD donor and passionate volunteer Donald E. Newhouse. Mr. Newhouse’s $20MM gift,…
Target ALS and AFTD Announce $5MM in Grants for Research Targeting Treatments and Biomarkers
Today, Target ALS and AFTD announced $5 million in funding awards for work by six research teams to aid in the discovery of biomarkers and viable treatments for ALS and frontotemporal degeneration. ALS and FTD overlap in genetic causes and…
Communications Strategist Kristin Holloway Joins AFTD’s Board of Directors
Today, The Association for Frontotemporal Degeneration (AFTD) announced that Kristin Holloway has joined its Board of Directors. This appointment was made effective April 18. After experiencing a sequence of unexplained changes in behavior and personality, Ms. Holloway’s husband, Lee Holloway,…
Major Research Funding for Blood Test to Accelerate Clinical Trials for New FTD Therapies
The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced today a major funding investment to the Bluefield Project to Cure FTD. The award is the first FTD investment through ADDF’s Diagnostics Accelerator, an initiative aimed to fast…
Fourth Annual AFTD Benefit Raises More Than $2 Million in Support of Frontotemporal Degeneration Research, Support and Awareness
AFTD held its annual Hope Rising Benefit on Wednesday night, raising more than $2 million in support of the organization’s mission. More than 550 attended the event at The Pierre Hotel in New York, including people living with FTD, care…